Smoldering multiple myeloma: biology, clinical manifestations and management

References

• Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980;302(24):1347–1349.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol. 2003;121(5):749–757.
   PubMed Web of Science ®Google Scholar
• Ravindran A, Bartley AC, Holton SJ, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6(10):e486.
   PubMedGoogle Scholar
• Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk smoldering myeloma. N Engl J Med. 2013;369(18):1762–1763.
   PubMed Web of Science ®Google Scholar
• Fermand JP, Bridoux F, Dispenzieri A et al. Monoclonal gammapathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478–1485
   PubMed Web of Science ®Google Scholar
• Fernand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammapathy of renal significance (MGRS). Blood. 2013;122(22):3583–3590.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med. 2011;365(5):474–475.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high- risk smoldering multiple myeloma. Leukemia. 2013;27(4):941–946.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol. 2010;28(9):1606–1610.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Moulopoulos LA, Terpos E, et al. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. Leukemia. 2014;28(12):2402–2403.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548.
   Web of Science ®Google Scholar
• Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;2456:1121–1127.
   Google Scholar
• Hillengass J, Usmani S, Rajkumar SV, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019;20:e302–e312.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammapathy of undetermined significance. N Engl J Med. 2002;346(8):564–569.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356(25):2582–2590.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–789.
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales MB, Mateo G, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood. 2007;110(7):2586–2592.
   PubMed Web of Science ®Google Scholar
• Neben K, Jauch A, Hielscher T, et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol. 2013;31(34):4325–4332.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gupta V, Fonseca R, et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia. 2013;27(8):1738–1744.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Waheed S, et al. Clinical, genome, and imaging predictors of myeloma progression from asymmtomatic monoclonal gammapathies (SWOG S0120). Blood. 2014;123(1):78–85.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.
   PubMedGoogle Scholar
• Mateos MV, Kumar S, Dimopoulos MA, et al. International myeloma working group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10(10):102.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Kyle RA, Larson DR, et al. High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma. Leukemia. 2013;27(3):680–685.
   PubMed Web of Science ®Google Scholar
• Gonsalves WI, Rajkumar SV, Dispenzieri A, et al. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression. Leukemia. 2017;31(1):130–135.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103.
   Google Scholar
• Madan S, Kyle RA, Greipp PR. Plasma cell labeling index in the evaluation of smoldering (asymptomatic) multiple myeloma. Mayo Clin Proc. 2010;85(3):300.
   PubMed Web of Science ®Google Scholar
• Aljama MA, Sidiqi MH, Lakshman A, et al. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. Blood Adv. 2018;2(22):3149–3154.
   PubMed Web of Science ®Google Scholar
• Ravi PSK, Larsen JT, Gonsalves WI, et al. Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J. 2016;6(7):e454.2.2.
   Google Scholar
• Bolli N, Maura F, Minvielle S, et al. Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018;9(1):3363.
   PubMedGoogle Scholar
• Merz M, Hielscher T, Schult D et al. Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma. Leukemia. 2020;34:1192–1196.
   PubMed Web of Science ®Google Scholar
• Dutta AK, Lynn Fink J, Grady JP et al. Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2019;33:457–468.
   PubMed Web of Science ®Google Scholar
• Bustoros M, Sklaventis-Pistofidis R, Park J et al. Genomic profiling of smoldering multiple myeloma identifies patients at high risk of disease progression. J Clin Oncol. 2020;38:2380–2389.
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sexton R, Das R, et al. Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammapathy. Blood. 2015;126(22):2475–2478.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Hernández M-T, Giraldo P, et al. Lenalidomide plus dexamethasone versus observation in patients with high risk smoldering multiple myeloma (QuiReDex): long-term follow up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17(8):1127–1136.893n.
   PubMed Web of Science ®Google Scholar
• Lonial S, Jacobus SJ, Weiss M, et al. E3A06: randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. J Clin Oncol. 2019;37:8001.
   Web of Science ®Google Scholar
• Landgren CO, Chari A, Cohen YC, et al. Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): centaurus, a randomized, open-label, multicenter phase 2 study. Leukemia. 2020;34(7):1840–1852.
   PubMed Web of Science ®Google Scholar
• Manasanch EE, Jagannath S, Lee HC. A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM). Blood. 2019;134(Supplement_1):3116.
   Google Scholar
• Busturos M, Liu CJ, Reyes K et al. Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood. 2018; 132 (Supplement 1): 804.
   Google Scholar
• Mateos MV, Martinez Lopez J, Rodriguez-Otero P, et al. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd. Blood. 2017;130:402.
   Web of Science ®Google Scholar
• Kazandjian D, Hill E, Morrison C, et al. Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (–R): a phase 2 clinical and correlative study. Blood. 2020;136(Supplement_1):43–45.
   Google Scholar